Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: avastin + roche + more  Related to the article below (Last Update: 7/8/2008)

Cancer Drug Avastin's Quality, Price Questioned
eMaxHealth.com, NC -
Cancer drug Avastin is found to cost more than it should, taking into consideration the fact that it doesn't significantly improve quality of life or ...

Dog Flu Diet and Diseases
New York Times Examines Benefits, Costs of Cancer Drug Avastin
Kaiser network.org, DC - Jul 7, 2008
Genentech and its partner Roche, as well as the National Cancer Institute are beginning studies involving more than 26000 people with colon, lung and breast ...
Costly cancer drug offers hope, but also a dilemma Sarasota Herald-Tribune
Payoffs of expensive cancer drug Avastin are debated Boston Globe
all 73 news articles »
The NYT On Avastin
Forbes, NY - Jul 6, 2008
Genentech and Roche have spent more than $2.25 billion to develop Avastin. That's an interesting figure -- about as much as the drug made in sales last year ...
GlaxoSmithKline: NICE says no to Tyverb
Trading Markets (press release), CA -
Together with the recent termination of NICE's appraisal of Roche's Avastin (bevacizumab) for use in breast and lung cancer and BMS/Merck's Erbitux ...
Roche's Avastin prolongs colorectal cancer patients survival
Reuters - Jun 30, 2008
At 0845 GMT, Roche shares were up nearly 1 percent at 176.50 Swiss francs. Data from the randomized, controlled Phase III AVF2107 study involving more than ...OTC:RHHBY - SWF:RO - PINK:RHHGY
Roche CEO: Emphasizing drugs for primary care
FierceBiotech, DC - Jul 2, 2008
By John Carroll The new CEO at Roche is sending out some strong signals that the pharma giant's development process will include more new therapies for ...
Roche CEO Won?t Shy Away from Primary-Care Drugs Wall Street Journal Blogs
all 10 news articles »
Roche plan gives US firms chance to stockpile Tamiflu
Pharma Times (subscription), UK - Jun 27, 2008
He described the situation as ?unfortunate?, noting that Avastin in this indication is already provided by healthcare systems in 14 European countries where ...

ITV.com
Roche decision denies cancer drug to Britons
Financial Times, UK - Jun 25, 2008
The National Institute for Clinical Health and Excellence, or Nice, has advised against the National Health Service using Avastin as a first-line treatment ...
NICE rejects cancer drug in clash with Roche International Herald Tribune
UK drug cost watchdog NICE expects funding boost guardian.co.uk
Drugs and value Financial Times
Financial Times
all 366 news articles »
More NICE debate over cancer meds
FiercePharma, DC - Jun 27, 2008
Yesterday, you'll recall, NICE said it was rejecting Roche's Avastin for National Health Service use because it lacked that data. Merck Serono's Erbitux is ...
Roche, NICE in Avastin data standoff FiercePharma
UK aims for quicker adoption of new meds FiercePharma
all 3 news articles »
Cancer mum's new hope for more time
Journal Live, UK - Jun 30, 2008
Mother-of-one Karen Gault is fighting terminal bowel cancer and has paid for all of her medical treatment privately after opting to fund the drug Avastin. ...
More patients to get opportunity to participate in clinical trials Cancer Research UK - News & Resources
Cancer drug pledge gets cautious welcome Oxford Mail
Easier drug availability key part of NHS reforms InTheNews.co.uk
Healthcare Digital
all 16 news articles »
Source: Google News

EGF105084, a phase II study of lapatinib for brain metastases in patients (pts) with HER2+ breast … -
NU Lin, V Dieras, D Paul, D Lossignol, C … - Proc Am Soc Clin Oncol, 2007 - pediatricca.asco.org
... cancer: bevacizumab and lapatinib. J Natl Compr Canc Netw, United States Vol 5,
No 3 (4/19/2007): pp. 314-23 PMID: 17439759 [PubMed - in process]. More... ...

Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and mullerian … -
… , DS Dizon, SA Cannistra, M Roche, CN Krasner, ST … - J Clin Oncol, 2007 - opl.asco.org
... SM Campos, DS Dizon, SA Cannistra, M. Roche, CN Krasner, ST Berlin ... Safety of maintenance
bevacizumab after first-line chemotherapy for advanced ovarian ... More... ...

Bevacizumab as a Potent Inhibitor of Inflammatory Corneal Angiogenesis and Lymphangiogenesis -
F Bock, J Onderka, T Dietrich, B Bachmann, FE … - Investigative Ophthalmology & Visual Science, 2007 - ARVO
... s instructions (Cell Proliferation ELISA for BrdU; Roche). ... injected, to analyze their
binding to immobilized bevacizumab. ... shown in Figure 3 , a more than more ...

Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study -
ML Abrah?m-Marin, CF Cort?s-Luna, G ?lvarez- … - Graefe's Archive for Clinical and Experimental Ophthalmology, 2007 - Springer
... was placed and 0.1 mL of bevacizumab (Roche) 25 mg ... who gained three lines or more
of BCVA ... EN, Venkatraman AS (2005) Systemic bevacizumab (Avastin) therapy for ...

Update on Capecitabine in Colorectal Cancer -
HJ Schmoll, D Arnold - The Oncologist, 2006 - AlphaMed Press
... Grade 3?4 neuropathy was more common with FUFOX than with ... cancer xenografts, there
is synergy between capecitabine and bevacizumab (Avastin?, Roche Ltd.) [29 ...

[CITATION] Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive … -
W Soliman, H Lund-Andersen, M Larsen - Acta Ophthalmologica Scandinavica, 2006 - Blackwell Synergy
... for stereopsis, the patient was offered and accepted open-label treatment using
1 mg (0.04 ml) intravitreal bevacizumab (Avastin; Roche, Copenhagen, Denmark). ...

Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients … -
KD Miller, LI Chap, FA Holmes, MA Cobleigh, PK … - Journal of Clinical Oncology, 2005 - jco.ascopubs.org
... Frankie A. Holmes, Amgen, Pfizer, Roche; Melody A ... of these categories, or for more
information about ... long-term therapy with bevacizumab (Avastin) in solid tumors ...

Penetration of Bevacizumab through the Retina after Intravitreal Injection in the Monkey -
P Heiduschka, H Fietz, S Hofmeister, S Schultheiss … - Investigative Ophthalmology & Visual Science, 2007 - ARVO
... in its commercial formulation (Avastin; Roche) through the ... M?ller cells were much
more activated, as can ... red) 7 days after intravitreal injection of Avastin. ...

Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC-- …
SR Berry, D Cunningham, M Michael, M Dibartolomeo, … - ASCO Meeting Abstracts, 2006 - meeting.ascopubs.org
... Germany; Parexel, Paris, France; Roche, Basel, Switzerland ... metastatic colorectal
cancer (mCRC), bevacizumab (BEV) increased ... events (TE) occurred more often in ...

Intravitreal Bevacizumab for the Treatment of Retinal Angiomatous Proliferation
C Costagliola, MR Romano, R dell?Omo, U Cipollone … - American Journal of Ophthalmology, 2007 - Elsevier
... 12 months after the first IVB (Avastin, [Roche Registration Ltd ... Reinjections of
bevacizumab were scheduled at least four ... CRT) documented by OCT of more than 100 ...

Source: Google Scholar
 

Roche aims to make Avastin more affordable in UK

Last Updated: 2007-05-10 12:30:11 -0400 (Reuters Health)

LONDON - Switzerland's Roche Holding AG launched blockbuster drug bevacizumab (Avastin) for breast cancer in Britain on Thursday and said it was working on ways to make the costly medicine more affordable.

Avastin was originally developed for colorectal cancer, but it has also proved effective in treating metastatic breast cancer when given alongside chemotherapy. The current recommended dose in breast cancer, however, is twice that for bowel cancer, pushing up the annual cost of the treatment to around 42,000 pounds ($83,680) per patient.

"We recognise that is going to be a challenge for the system here, and we are looking at ways to address affordability -- and we should be making an announcement at the beginning of June," a Roche spokesman said.

Article continues below and (thank you)
 

The cost of Avastin is likely to prove particularly sensitive in Britain, given past controversy over access to another -- cheaper -- breast cancer drug, Herceptin, which is also sold by Roche.

The cost effectiveness of new drugs also receives an especially high profile in Britain, because they are reviewed by the National Institute for Health and Clinical Excellence.

But Roche is also looking at ways to address the affordability of Avastin in other European countries.

William Burns, head of pharmaceuticals, said last month it was studying ways to limit the cost in Europe, following a successful price-capping programme by majority-owned partner Genentech Inc. in the United States.

Roche is the world's biggest maker of cancer drugs, and some analysts say Avastin will become its biggest seller in the years ahead.

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 
 
 
Google
Web www.iconocast.com
 
 
Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

 © 2002-2006

Keywords:

Contact Iconocast